New York S 3185: Prohibits the taking of horseshoe crabs for commercial and biomedical purposes

Bill Text

Bill Search and Legislative Information | New York State Assembly 

• 

• 

• 

• 

• 

• 

• 

• 

 Skip to main content 

 New York State Assembly

 Speaker Carl E. Heastie

 --> 
 --> 

 --> 

• 
 Assembly Members 

• 
 Legislative Info 

• 
 Public Hearings 

• 
 Speaker's Press 

• 
 Assembly Reports 

• 
 Committees & More 

• Bill Search Home
• Laws
• Legislative Calendar
• Public Hearing Schedule
• Assembly Calendars
• Assembly Committee Agenda 

 Javascript must be enabled to properly view this page. 

 Bill No.: 

• Summary 
• Actions 
• Committee&nbspVotes 
• Floor&nbspVotes 
• Memo 
• Text 
• LFIN 
• Chamber&nbspVideo/Transcript 
S03185 Summary:

BILL NOS03185A

&nbsp

SAME ASSAME AS A01921-B

&nbsp

SPONSORRIVERA

&nbsp

COSPNSRFERNANDEZ

&nbsp

MLTSPNSR

&nbsp

Amd §§3216, 3221 & 4303, Ins L

&nbsp

Provides outpatient insurance coverage for non-pharmacological treatments and non-opioid drugs for chronic pain.

Go to top S03185 Actions:

BILL NOS03185A

&nbsp

01/24/2025REFERRED TO INSURANCE

05/05/2025REPORTED AND COMMITTED TO FINANCE

01/07/2026REFERRED TO INSURANCE

04/07/2026AMEND (T) AND RECOMMIT TO INSURANCE

04/07/2026PRINT NUMBER 3185A

Go to topS03185 Committee&nbspVotes:

Go to topS03185 Floor&nbspVotes:

There are no Assembly votes for this bill in this legislative session.

Go to topS03185 Text:

 STATE OF NEW YORK
 ________________________________________________________________________

 3185--A

 2025-2026 Regular Sessions

 IN SENATE

 January 24, 2025
 ___________

 Introduced by Sens. RIVERA, FERNANDEZ -- read twice and ordered printed,
 and when printed to be committed to the Committee on Insurance --
 recommitted to the Committee on Insurance in accordance with Senate
 Rule 6, sec. 8 -- committee discharged, bill amended, ordered
 reprinted as amended and recommitted to said committee

 AN ACT to amend the insurance law, in relation to providing insurance
 coverage for non-pharmacological treatments and non-opioid drugs for
 chronic pain

 The People of the State of New York, represented in Senate and Assem-
 bly, do enact as follows:

 1 Section 1. Subsection (i) of section 3216 of the insurance law is
 2 amended by adding a new paragraph 42 to read as follows:
 3 (42) (A) Every policy that provides medical, major medical, or similar
 4 comprehensive-type coverage that provides coverage for pain shall
 5 provide outpatient coverage for a minimum of three non-pharmacological
 6 treatments of chronic pain, and a minimum of two non-opioid drugs
 7 approved by the United States Food and Drug Administration (FDA) for the
 8 treatment of acute or chronic pain. Such non-pharmacological non-opioid
 9 treatments shall include at least one of each of the following treatment
 10 types: (i) restorative treatments such as massage therapy; (ii) behav-
 11 ioral treatments such as cognitive behavioral therapy; and (iii) comple-
 12 mentary treatments such as acupuncture. Access to non-pharmacological
 13 treatments and non-opioid drugs shall be comparable to that of other
 14 covered services. Coverage shall be comparable for services provided by
 15 licensed professionals.
 16 (B) Coverage under this subsection shall not apply financial require-
 17 ments or treatment limitations to non-opioid treatment of chronic pain
 18 that are more restrictive than either of the following: the predominant
 19 financial requirements and treatment limitations applied to substantial-
 20 ly all medical benefits covered by the contract; and the financial
 21 requirements and treatment limitations applied to any opioid-based

 EXPLANATION--Matter in italics (underscored) is new; matter in brackets
 [ ] is old law to be omitted.
 LBD05350-07-6

 S. 3185--A 2

 1 treatment of chronic pain. Coverage under this paragraph shall not
 2 disadvantage or discourage any non-opioid drug approved by the United
 3 States Food and Drug Administration (FDA) for the treatment of chronic
 4 or acute pain relative to any opioid drug for the treatment of chronic
 5 or acute pain, where impermissible disadvantaging or discouragement
 6 includes, without limitation: designating any such non-opioid drug as a
 7 non-preferred drug if any opioid or narcotic drug is designated as a
 8 preferred drug; or establishing more restrictive or more extensive
 9 utilization controls including, but not limited to, more restrictive or
 10 more extensive financial requirements, prior authorization, or step
 11 therapy requirements, for such non-opioid drug than the least restric-
 12 tive or extensive utilization controls applicable to any such opioid or
 13 narcotic drug.
 14 (C) For the purposes of this paragraph the following terms shall have
 15 the following meanings:
 16 (i) "financial requirement" means deductible, co-payments, co-insu-
 17 rance and out-of-pocket expenses;
 18 (ii) "predominant" means that a financial requirement or treatment
 19 limitation is the most common or frequent of such type of limit or
 20 requi